Psoriasis in Children and Adolescents: Diagnosis, Management and Comorbidities

I M G J Bronckers, A S Paller, M J van Geel, P C M van de Kerkhof, M M B Seyger, I M G J Bronckers, A S Paller, M J van Geel, P C M van de Kerkhof, M M B Seyger

Abstract

Psoriasis is a common chronic immune-mediated inflammatory skin disorder and begins in childhood in almost one-third of the cases. Although children present with the same clinical subtypes of psoriasis seen in adults, lesions may differ in distribution and morphology, and their clinical symptoms at presentation may vary from those reported by adult patients. Nevertheless, diagnosis of psoriasis is primarily based on clinical features. Pediatric psoriasis can have a profound long-term impact on the psychological health of affected children. Additionally, pediatric psoriasis has been associated with certain comorbidities, such as obesity, hypertension, hyperlipidemia, diabetes mellitus and rheumatoid arthritis, making early diagnosis and management essential. As guidelines are lacking and most (systemic) treatments are not approved for use in children, treatment of pediatric psoriasis remains a challenge. A prospective, multicenter, international registry is needed to evaluate these treatments in a standardized manner and ultimately to develop international guidelines on pediatric psoriasis. This article reviews current concepts in pediatric psoriasis including epidemiology, clinical features, diagnosis, the role of topical and systemic agents and the association with other morbidities in childhood.

Figures

Fig. 1
Fig. 1
Pediatric definition of the metabolic syndrome. Figure adapted from de Ferranti et al. [124]

References

    1. Augustin M, Glaeske G, Radtke MA, Christophers E, Reich K, Schafer I. Epidemiology and comorbidity of psoriasis in children. Br J Dermat. 2010;162(3):633–636.
    1. Christophers E. Psoriasis—epidemiology and clinical spectrum. Clin Exp Dermatol. 2001;26(4):314–320.
    1. Parisi R, Symmons DP, Griffiths CE, Ashcroft DM. Identification, Management of Psoriasis and Associated Comorbidity Project. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Invest Dermatol. 2013;133(2):377–385.
    1. Gelfand JM, Weinstein R, Porter SB, Neimann AL, Berlin JA, Margolis DJ. Prevalence and treatment of psoriasis in the United Kingdom: a population-based study. Arch Dermatol. 2005;141(12):1537–1541.
    1. Raychaudhuri SP, Gross J. A comparative study of pediatric onset psoriasis with adult onset psoriasis. Pediatr Dermatol. 2000;17(3):174–178.
    1. Tollefson MM, Crowson CS, McEvoy MT, Maradit Kremers H. Incidence of psoriasis in children: a population-based study. J Am Acad Dermatol. 2010;62(6):979–987.
    1. de Jager ME, De Jong EM, Evers AW, Van De Kerkhof PC, Seyger MM. The burden of childhood psoriasis. Pediatr Dermatol. 2011;28(6):736–737.
    1. Bilgic A, Bilgic O, Akis HK, Eskioglu F, Kilic EZ. Psychiatric symptoms and health-related quality of life in children and adolescents with psoriasis. Pediatr Dermatol. 2010;27(6):614–617.
    1. Oostveen AM, de Jager ME, van de Kerkhof PC, Donders AR, de Jong EM, Seyger MM. The influence of treatments in daily clinical practice on the Children’s Dermatology Life Quality Index in juvenile psoriasis: a longitudinal study from the Child-CAPTURE patient registry. Br J Dermatol. 2012;167(1):145–149.
    1. Paller AS, Mercy K, Kwasny MJ, Choon SE, Cordoro KM, Girolomoni G, et al. Association of pediatric psoriasis severity with excess and central adiposity: an international cross-sectional study. JAMA Dermatol. 2013;149(2):166–176.
    1. Becker L, Tom WL, Eshagh K, Benjamin LT, Paller AS. Excess adiposity preceding pediatric psoriasis. JAMA Dermatol. 2014;150(5):573–574.
    1. Kimball AB, Wu EQ, Guerin A, Yu AP, Tsaneva M, Gupta SR, et al. Risks of developing psychiatric disorders in pediatric patients with psoriasis. J Am Acad Dermatol. 2012;67(4):651–657.
    1. De Jager ME, Van de Kerkhof PC, De Jong EM, Seyger MM. Epidemiology and prescribed treatments in childhood psoriasis: a survey among medical professionals. J Dermatol Treat. 2009;20(5):254–258.
    1. Matusiewicz D, Koerber A, Schadendorf D, Wasem J, Neumann A. Childhood psoriasis—an analysis of German health insurance data. Pediatr Dermatol. 2014;31(1):8–13.
    1. Yang YC, Cheng YW, Lai CS, Chen W. Prevalence of childhood acne, ephelides, warts, atopic dermatitis, psoriasis, alopecia areata and keloid in Kaohsiung County, Taiwan: a community-based clinical survey. J Eur Acad Dermatol Venereol: JEADV. 2007;21(5):643–649.
    1. Chen GY, Cheng YW, Wang CY, Hsu TJ, Hsu MM, Yang PT, et al. Prevalence of skin diseases among schoolchildren in Magong, Penghu, Taiwan: a community-based clinical survey. Journal of the Formosan Medical Association = Taiwan yi zhi. 2008;107(1):21–29.
    1. Griffiths CE, Barker JN. Pathogenesis and clinical features of psoriasis. Lancet. 2007;370(9583):263–271.
    1. Tsankov N, Angelova I, Kazandjieva J. Drug-induced psoriasis. Recognition and management. Am J Clin Dermatol. 2000;1(3):159–165.
    1. Cullen G, Kroshinsky D, Cheifetz AS, Korzenik JR. Psoriasis associated with anti-tumour necrosis factor therapy in inflammatory bowel disease: a new series and a review of 120 cases from the literature. Aliment Pharmacol Ther. 2011;34(11–12):1318–1327.
    1. Perman MJ, Lovell DJ, Denson LA, Farrell MK, Lucky AW. Five cases of anti-tumor necrosis factor alpha-induced psoriasis presenting with severe scalp involvement in children. Pediatr Dermatol. 2012;29(4):454–459.
    1. Fan X, Xiao FL, Yang S, Liu JB, Yan KL, Liang YH, et al. Childhood psoriasis: a study of 277 patients from China. J Eur Acad Dermatol Venereol: JEADV. 2007;21(6):762–765.
    1. Kumar B, Jain R, Sandhu K, Kaur I, Handa S. Epidemiology of childhood psoriasis: a study of 419 patients from northern India. Int J Dermatol. 2004;43(9):654–658.
    1. Morris A, Rogers M, Fischer G, Williams K. Childhood psoriasis: a clinical review of 1262 cases. Pediatr Dermatol. 2001;18(3):188–198.
    1. Nanda A, Kaur S, Kaur I, Kumar B. Childhood psoriasis: an epidemiologic survey of 112 patients. Pediatr Dermatol. 1990;7(1):19–21.
    1. Mercy K, Kwasny M, Cordoro KM, Menter A, Tom WL, Korman N, et al. Clinical manifestations of pediatric psoriasis: results of a multicenter study in the United States. Pediatr Dermatol. 2013;30(4):424–428.
    1. Chiam LY, de Jager ME, Giam YC, de Jong EM, van de Kerkhof PC, Seyger MM. Juvenile psoriasis in European and Asian children: similarities and differences. Br J Dermatol. 2011;164(5):1101–1103.
    1. al-Fouzan AS, Nanda A. A survey of childhood psoriasis in Kuwait. Pediatr Dermatol. 1994;11(2):116–119.
    1. Seyhan M, Coskun BK, Saglam H, Ozcan H, Karincaoglu Y. Psoriasis in childhood and adolescence: evaluation of demographic and clinical features. Pediatr Int. 2006;48(6):525–530.
    1. Shah KN. Diagnosis and treatment of pediatric psoriasis: current and future. Am J Clin Dermatol. 2013;14(3):195–213.
    1. Kwon HH, Na SJ, Jo SJ, Youn JI. Epidemiology and clinical features of pediatric psoriasis in tertiary referral psoriasis clinic. J Dermatol. 2012;39(3):260–264.
    1. Dogra S, Kaur I. Childhood psoriasis. Indian J Dermatol Venereol Leprol. 2010;76(4):357–365.
    1. Tollefson MM. Diagnosis and management of psoriasis in children. Pediatr Clin North Am. 2014;61(2):261–277.
    1. Benoit S, Hamm H. Childhood psoriasis. Clin Dermatol. 2007;25(6):555–562.
    1. Silverberg NB. Pediatric psoriasis: an update. Ther Clin Risk Manag. 2009;5:849–856.
    1. Howard R, Tsuchiya A. Adult skin disease in the pediatric patient. Dermatol Clin. 1998;16(3):593–608.
    1. Busch AL, Landau JM, Moody MN, Goldberg LH. Pediatric psoriasis. Skin Therapy Lett. 2012;17(1):5–7.
    1. Martin BA, Chalmers RJ, Telfer NR. How great is the risk of further psoriasis following a single episode of acute guttate psoriasis? Arch Dermatol. 1996;132(6):717–718.
    1. Setta-Kaffetzi N, Navarini AA, Patel VM, Pullabhatla V, Pink AE, Choon SE, et al. Rare pathogenic variants in IL36RN underlie a spectrum of psoriasis-associated pustular phenotypes. J Invest Dermatol. 2013;133(5):1366–1369.
    1. Liao PB, Rubinson R, Howard R, Sanchez G, Frieden IJ. Annular pustular psoriasis—most common form of pustular psoriasis in children: report of three cases and review of the literature. Pediatr Dermatol. 2002;19(1):19–25.
    1. Brazzelli V, Carugno A, Alborghetti A, Grasso V, Cananzi R, Fornara L, et al. Prevalence, severity and clinical features of psoriasis in fingernails and toenails in adult patients: Italian experience. J Eur Acad Dermatol Venereol: JEADV. 2012;26(11):1354–1359.
    1. Schachner LA, Hansen RC. Pediatric dermatology. 4. Philadelphia: Elsevier Ltd; 2011.
    1. Stoll ML, Zurakowski D, Nigrovic LE, Nichols DP, Sundel RP, Nigrovic PA. Patients with juvenile psoriatic arthritis comprise two distinct populations. Arthritis Rheum. 2006;54(11):3564–3572.
    1. Flato B, Lien G, Smerdel-Ramoya A, Vinje O. Juvenile psoriatic arthritis: longterm outcome and differentiation from other subtypes of juvenile idiopathic arthritis. J Rheumatol. 2009;36(3):642–650.
    1. Krumrey-Langkammerer M, Hafner R. Evaluation of the ILAR criteria for juvenile idiopathic arthritis. J Rheumatol. 2001;28(11):2544–2547.
    1. Saurenmann RK, Levin AV, Feldman BM, Rose JB, Laxer RM, Schneider R, et al. Prevalence, risk factors, and outcome of uveitis in juvenile idiopathic arthritis: a long-term followup study. Arthritis Rheum. 2007;56(2):647–657.
    1. Danner S, Sordet C, Terzic J, Donato L, Velten M, Fischbach M, et al. Epidemiology of juvenile idiopathic arthritis in Alsace, France. J Rheumatol. 2006;33(7):1377–1381.
    1. Butbul Aviel Y, Tyrrell P, Schneider R, Dhillon S, Feldman BM, Laxer R, et al. Juvenile psoriatic arthritis (JPsA): juvenile arthritis with psoriasis? Pediatr Rheumatol Online J. 2013;11(1):11.
    1. Sticherling M, Minden K, Kuster RM, Krause A, Borte M. Psoriasis and psoriasis arthritis in childhood and adolescence. Overview and consensus statement of the 9th Worlitz Expert Round Table Discussion 2006 for the Society for Child and Adolescent Rheumatology. Z Rheumatol. 2007;66(4):349–354.
    1. Zachariae H. Prevalence of joint disease in patients with psoriasis: implications for therapy. Am J Clin Dermatol. 2003;4(7):441–447.
    1. Wittkowski KM, Leonardi C, Gottlieb A, Menter A, Krueger GG, Tebbey PW, et al. Clinical symptoms of skin, nails, and joints manifest independently in patients with concomitant psoriasis and psoriatic arthritis. PLoS One. 2011;6(6):e20279.
    1. Nestle FO, Kaplan DH, Barker J. Psoriasis. N Engl J Med. 2009;361(5):496–509.
    1. Murphy M, Kerr P, Grant-Kels JM. The histopathologic spectrum of psoriasis. Clin Dermatol. 2007;25(6):524–528.
    1. Stahle M, Atakan N, Boehncke WH, Chimenti S, Dauden E, Giannetti A, et al. Juvenile psoriasis and its clinical management: a European expert group consensus. J Ger Soc Dermatol. 2010;8(10):812–818.
    1. Moscarella E, Longo C, Zalaudek I, Argenziano G, Piana S, Lallas A. Dermoscopy and confocal microscopy clues in the diagnosis of psoriasis and porokeratosis. J Am Acad Dermatol. 2013;69(5):e231–e233.
    1. Lallas A, Kyrgidis A, Tzellos TG, Apalla Z, Karakyriou E, Karatolias A, et al. Accuracy of dermoscopic criteria for the diagnosis of psoriasis, dermatitis, lichen planus and pityriasis rosea. Br J Dermatol. 2012;166(6):1198–1205.
    1. Luersen K, Davis SA, Kaplan SG, Abel TD, Winchester WW, Feldman SR. Sticker charts: a method for improving adherence to treatment of chronic diseases in children. Pediatr Dermatol. 2012;29(4):403–408.
    1. Tan X, Feldman SR, Chang J, Balkrishnan R. Topical drug delivery systems in dermatology: a review of patient adherence issues. Expert Opin Drug Deliv. 2012;9(10):1263–1271.
    1. Davis SA, Lin HC, Yu CH, Balkrishnan R, Feldman SR. Underuse of early follow-up visits: a missed opportunity to improve patients’ adherence. J Drugs Dermatol: JDD. 2014;13(7):833–836.
    1. Lara-Corrales I, Xi N, Pope E. Childhood psoriasis treatment: evidence published over the last 5 years. Rev Recent Clin Trials. 2011;6(1):36–43.
    1. Fotiadou C, Lazaridou E, Ioannides D. Management of psoriasis in adolescence. Adolesc Health Med Ther. 2014;5:25–34.
    1. Sticherling M, Augustin M, Boehncke WH, Christophers E, Domm S, Gollnick H, et al. Therapy of psoriasis in childhood and adolescence—a German expert consensus. J Ger Soc Dermatol. 2011;9(10):815–823.
    1. Bhutani T, Kamangar F, Cordoro KM. Management of pediatric psoriasis. Pediatr Ann. 2012;41(1):e1–e7.
    1. de Jager ME, de Jong EM, van de Kerkhof PC, Seyger MM. Efficacy and safety of treatments for childhood psoriasis: a systematic literature review. J Am Acad Dermatol. 2010;62(6):1013–1030.
    1. Kimball AB, Gold MH, Zib B, Davis MW, Clobetasol Propionate Emulsion Formulation Foam Phase IIICSG Clobetasol propionate emulsion formulation foam 0.05 %: review of phase II open-label and phase III randomized controlled trials in steroid-responsive dermatoses in adults and adolescents. J Am Acad Dermatol. 2008;59(3):448–454.
    1. Herz G, Blum G, Yawalkar S. Halobetasol propionate cream by day and halobetasol propionate ointment at night for the treatment of pediatric patients with chronic, localized plaque psoriasis and atopic dermatitis. J Am Acad Dermatol. 1991;25(6 Pt 2):1166–1169.
    1. Darley CR, Cunliffe WJ, Green CM, Hutchinson PE, Klaber MR, Downes N. Safety and efficacy of calcipotriol ointment (Dovonex) in treating children with psoriasis vulgaris. Br J Dermatol. 1996;135(3):390–393.
    1. Oranje AP, Marcoux D, Svensson A, Prendiville J, Krafchik B, Toole J, et al. Topical calcipotriol in childhood psoriasis. J Am Acad Dermatol. 1997;36(2 Pt 1):203–208.
    1. van de Kerkhof PC, Hoffmann V, Anstey A, Barnes L, Bolduc C, Reich K, et al. A new scalp formulation of calcipotriol plus betamethasone dipropionate compared with each of its active ingredients in the same vehicle for the treatment of scalp psoriasis: a randomized, double-blind, controlled trial. Br J Dermatol. 2009;160(1):170–176.
    1. van Geel MJ, Mul K, Oostveen AM, van de Kerkhof PC, de Jong EM, Seyger MM. Calcipotriol/betamethasone dipropionate ointment in mild-to-moderate paediatric psoriasis: long-term daily clinical practice data in a prospective cohort. Br J Dermatol. 2014;171(2):363–369.
    1. Gooderham M, Debarre JM, Keddy-Grant J, Xu Z, Kurvits M, Goodfield M. Safety and efficacy of calcipotriol plus betamethasone dipropionate gel in the treatment of scalp psoriasis in adolescents 12–17 years of age. Br J Dermatol. 2014;171(6):1470–1477.
    1. Oostveen AM, de Jong EM, Donders AR, van de Kerkhof PC, Seyger MM. Treatment of paediatric scalp psoriasis with calcipotriene/betamethasone dipropionate scalp formulation: effectiveness, safety and influence on children’s quality of life in daily practice. J Eur Acad Dermatol Venereol: JEADV. 2015;29(6):1193–1197.
    1. Wang C, Lin A. Efficacy of topical calcineurin inhibitors in psoriasis. J Cutan Med Surg. 2014;18(1):8–14.
    1. Steele JA, Choi C, Kwong PC. Topical tacrolimus in the treatment of inverse psoriasis in children. J Am Acad Dermatol. 2005;53(4):713–716.
    1. Brune A, Miller DW, Lin P, Cotrim-Russi D, Paller AS. Tacrolimus ointment is effective for psoriasis on the face and intertriginous areas in pediatric patients. Pediatr Dermatol. 2007;24(1):76–80.
    1. de Jager ME, van de Kerkhof PC, de Jong EM, Seyger MM. Dithranol therapy in childhood psoriasis: unjustifiably on the verge of falling into oblivion. Dermatology. 2010;220(4):329–332.
    1. Oostveen AM, Beulens CA, van de Kerkhof PC, de Jong EM, Seyger MM. The effectiveness and safety of short-contact dithranol therapy in paediatric psoriasis: a prospective comparison of regular day care and day care with telemedicine. Br J Dermatol. 2014;170(2):454–457.
    1. Zamberk P, Velazquez D, Campos M, Hernanz JM, Lazaro P. Paediatric psoriasis—narrowband UVB treatment. J Eur Acad Dermatol Venereol: JEADV. 2010;24(4):415–419.
    1. Pavlovsky M, Baum S, Shpiro D, Pavlovsky L, Pavlotsky F. Narrow band UVB: is it effective and safe for paediatric psoriasis and atopic dermatitis? J Eur Acad Dermatol Venereol: JEADV. 2011;25(6):727–729.
    1. Lara-Corrales I, Ramnarine S, Lansang P. Treatment of childhood psoriasis with phototherapy and photochemotherapy. Clin Med Insights Pediatr. 2013;7:25–33.
    1. Jury CS, McHenry P, Burden AD, Lever R, Bilsland D. Narrowband ultraviolet B (UVB) phototherapy in children. Clin Exp Dermatol. 2006;31(2):196–199.
    1. Patel RV, Clark LN, Lebwohl M, Weinberg JM. Treatments for psoriasis and the risk of malignancy. J Am Acad Dermatol. 2009;60(6):1001–1017.
    1. Archier E, Devaux S, Castela E, Gallini A, Aubin F, Le Maitre M, et al. Carcinogenic risks of psoralen UV-A therapy and narrowband UV-B therapy in chronic plaque psoriasis: a systematic literature review. J Eur Acad Dermatol Venereol: JEADV. 2012;26(Suppl 3):22–31.
    1. Chen X, Yang M, Cheng Y, Liu GJ, Zhang M. Narrow-band ultraviolet B phototherapy versus broad-band ultraviolet B or psoralen-ultraviolet A photochemotherapy for psoriasis. Cochrane Database Syst Rev. 2013;10:CD009481.
    1. Zweegers J, de Jong EM, Nijsten TE, de Bes J, te Booij M, Bogonjen RJ, et al. Summary of the Dutch S3-guidelines on the treatment of psoriasis 2011. Dermatol Online J. 2014;20(3):1–112.
    1. van Geel MJ, Mul K, de Jager ME, van de Kerkhof PC, de Jong EM, Seyger MM. Systemic treatments in paediatric psoriasis: a systematic evidence-based update. J Eur Acad Dermatol Venereol: JEADV. 2015;29(3):425–437.
    1. Wright NA, Piggott CD, Eichenfield LF. The role of biologics and other systemic agents in the treatment of pediatric psoriasis. Semin Cutan Med Surg. 2010;29(1):20–27.
    1. Geel MJ, Oostveen AM, Hoppenreijs EP, Hendriks JC, Kerkhof PC, de Jong EM, et al. Methotrexate in pediatric plaque-type psoriasis: long-term daily clinical practice results from the Child-CAPTURE registry. J Dermatol Treat. 2015;20:1–7.
    1. Posso-De Los Rios CJ, Pope E, Lara-Corrales I. A systematic review of systemic medications for pustular psoriasis in pediatrics. Pediatr Dermatol. 2014;31(4):430–439.
    1. Marqueling AL, Cordoro KM. Systemic treatments for severe pediatric psoriasis: a practical approach. Dermatol Clin. 2013;31(2):267–288.
    1. Pathirana D, Ormerod AD, Saiag P, Smith C, Spuls PI, Nast A, et al. European S3-guidelines on the systemic treatment of psoriasis vulgaris. J Eur Acad Dermatol Venereol: JEADV. 2009;23(Suppl 2):1–70.
    1. Kaur I, Dogra S, De D, Kanwar AJ. Systemic methotrexate treatment in childhood psoriasis: further experience in 24 children from India. Pediatr Dermatol. 2008;25(2):184–188.
    1. Hashkes PJ, Becker ML, Cabral DA, Laxer RM, Paller AS, Rabinovich CE, et al. Methotrexate: new uses for an old drug. J Pediatr. 2014;164(2):231–236.
    1. Kilic SS, Hacimustafaoglu M, Celebi S, Karadeniz A, Ildirim I. Low dose cyclosporin A treatment in generalized pustular psoriasis. Pediatr Dermatol. 2001;18(3):246–248.
    1. Mahe E, Bodemer C, Pruszkowski A, Teillac-Hamel D, de Prost Y. Cyclosporine in childhood psoriasis. Arch Dermatol. 2001;137(11):1532–1533.
    1. Alli N, Gungor E, Karakayali G, Lenk N, Artuz F. The use of cyclosporin in a child with generalized pustular psoriasis. Br J Dermatol. 1998;139(4):754–755.
    1. Kim HS, Kim GM, Kim SY. Two-stage therapy for childhood generalized pustular psoriasis: low-dose cyclosporin for induction and maintenance with acitretin/narrowband ultraviolet B phototherapy. Pediatr Dermatol. 2006;23(3):306–308.
    1. Chao PH, Cheng YW, Chung MY. Generalized pustular psoriasis in a 6-week-old infant. Pediatr Dermatol. 2009;26(3):352–354.
    1. Sarkar S, Das K, Roychoudhury S, Shrimal A. Pseudotumor cerebri in a child treated with acitretin: a rare occurrence. Indian J Pharmacol. 2013;45(1):89–90.
    1. Cordoro KM. Management of childhood psoriasis. Adv Dermatol. 2008;24:125–169.
    1. Balak DM, Oostveen AM, Bousema MT, Venema AW, Arnold WP, Seyger MM, et al. Effectiveness and safety of fumaric acid esters in children with psoriasis: a retrospective analysis of 14 patients from The Netherlands. Br J Dermatol. 2013;168(6):1343–1347.
    1. Hoefnagel JJ, Thio HB, Willemze R. Bouwes Bavinck JN. Long-term safety aspects of systemic therapy with fumaric acid esters in severe psoriasis. Br J Dermatol. 2003;149(2):363–369.
    1. Gerdes S, Domm S, Mrowietz U. Long-term treatment with fumaric acid esters in an 11-year-old male child with psoriasis. Dermatology. 2011;222(3):198–200.
    1. Steeman AS, Balak DM, Seijger MMB, Thio HB, Bousema MT. Fumaraten bij een meisje van vijftien jaar met psoriasis! Nederlands Tijdschrift voor Dermatologie & Venereologie. 2012;22(5):308–311.
    1. Gunther CH. Successive use of fumaric acid esters for the treatment of psoriasis vulgaris in a 14-year-old patient [German] Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete. 2004;15(1):28–30.
    1. Paller AS, Siegfried EC, Langley RG, Gottlieb AB, Pariser D, Landells I, et al. Etanercept treatment for children and adolescents with plaque psoriasis. N Engl J Med. 2008;358(3):241–251.
    1. Luu M, Cordoro KM. The evolving role of biologics in the treatment of pediatric psoriasis. Skin Therapy Lett. 2013;18(2):1–4.
    1. Sukhatme SV, Gottlieb AB. Pediatric psoriasis: updates in biologic therapies. Dermatol Therapy. 2009;22(1):34–39.
    1. Paller AS, Siegfried EC, Eichenfield LF, Pariser D, Langley RG, Creamer K, et al. Long-term etanercept in pediatric patients with plaque psoriasis. J Am Acad Dermatol. 2010;63(5):762–768.
    1. Lovell DJ, Reiff A, Ilowite NT, Wallace CA, Chon Y, Lin SL, et al. Safety and efficacy of up to eight years of continuous etanercept therapy in patients with juvenile rheumatoid arthritis. Arthritis Rheum. 2008;58(5):1496–1504.
    1. Prince FH, Twilt M, ten Cate R, van Rossum MA, Armbrust W, Hoppenreijs EP, et al. Long-term follow-up on effectiveness and safety of etanercept in juvenile idiopathic arthritis: the Dutch national register. Ann Rheum Dis. 2009;68(5):635–641.
    1. Bellodi Schmidt F, Shah KN. Biologic response modifiers and pediatric psoriasis. Pediatr Dermatol. 2015;32(3):303–320.
    1. Dini V, Barbanera S, Romanelli M. Efficacy of adalimumab for the treatment of refractory paediatric acrodermatitis continua of hallopeau. Acta Dermato-Venereologica. 2013;93(5):588–589.
    1. Moretti D, Cianchi I, Vannucci G, Cimaz R, Simonini G. Psoriatic juvenile idiopathic arthritis associated with uveitis: a case report. Case Rep Rheumatol. 2013;2013:595890.
    1. A double blind study in pediatric subjects with chronic plaque psoriasis, studying adalimumab vs methotrexate [online]. . NLM identifier: NCT01251614. Accessed 4 May 2015.
    1. Fotiadou C, Lazaridou E, Giannopoulou C, Ioannides D. Ustekinumab for the treatment of an adolescent patient with recalcitrant plaque psoriasis. Eur J Dermatol: EJD. 2011;21(1):117–118.
    1. Dixit S, Shumack S, Fischer G. Ustekinumab in the treatment of severe paediatric psoriasis. Aust J Dermatol. 2013;54(2):147.
    1. AbuHilal M, Ho N. Successful treatment of severe psoriasis in an adolescent with ustekinumab. Pediatr Dermatol. 2015;32(3):377–380.
    1. A study of the safety and efficacy of ustekinumab in adolescent patients with psoriasis (CADMUS) [online]. . NLM identifier: NCT01090427. Accessed 28 December 2014.
    1. Augustin M, Reich K, Glaeske G, Schaefer I, Radtke M. Co-morbidity and age-related prevalence of psoriasis: analysis of health insurance data in Germany. Acta Dermato-Venereologica. 2010;90(2):147–151.
    1. Koebnick C, Black MH, Smith N, Der-Sarkissian JK, Porter AH, Jacobsen SJ, et al. The association of psoriasis and elevated blood lipids in overweight and obese children. J Pediatr. 2011;159(4):577–583.
    1. de Jager ME, van de Kerkhof PC, de Jong EM, Seyger MM. A cross-sectional study using the Children’s Dermatology Life Quality Index (CDLQI) in childhood psoriasis: negative effect on quality of life and moderate correlation of CDLQI with severity scores. Br J Dermatol. 2010;163(5):1099–1101.
    1. Mercy KM, Paller AS. The relationship between obesity and psoriasis in the pediatric population: implications and future directions. Cutis. 2013;92(3):107–109.
    1. Jensen P, Zachariae C, Christensen R, Geiker NR, Schaadt BK, Stender S, et al. Effect of weight loss on the severity of psoriasis: a randomized clinical study. JAMA Dermatol. 2013;149(7):795–801.
    1. de Ferranti SD, Gauvreau K, Ludwig DS, Neufeld EJ, Newburger JW, Rifai N. Prevalence of the metabolic syndrome in American adolescents: findings from the Third National Health and Nutrition Examination Survey. Circulation. 2004;110(16):2494–2497.
    1. Au SC, Goldminz AM, Loo DS, Dumont N, Levine D, Volf E, et al. Association between pediatric psoriasis and the metabolic syndrome. J Am Acad Dermatol. 2012;66(6):1012–1013.
    1. Mahe E, Maccari F, Beauchet A, Lahfa M, Barthelemy H, Reguiai Z, et al. Childhood-onset psoriasis: association with future cardiovascular and metabolic comorbidities. Br J Dermatol. 2013;169(4):889–895.
    1. Lewis-Jones MS, Finlay AY. The Children’s Dermatology Life Quality Index (CDLQI): initial validation and practical use. Br J Dermatol. 1995;132(6):942–949.
    1. Langley RG, Paller AS, Hebert AA, Creamer K, Weng HH, Jahreis A, et al. Patient-reported outcomes in pediatric patients with psoriasis undergoing etanercept treatment: 12-week results from a phase III randomized controlled trial. J Am Acad Dermatol. 2011;64(1):64–70.
    1. Akay A, Pekcanlar A, Bozdag KE, Altintas L, Karaman A. Assessment of depression in subjects with psoriasis vulgaris and lichen planus. J Eur Acad Dermatol Venereol: JEADV. 2002;16(4):347–352.
    1. Russo PA, Ilchef R, Cooper AJ. Psychiatric morbidity in psoriasis: a review. Aust J Dermatol. 2004;45(3):155–159.
    1. Remrod C, Sjostrom K, Svensson A. Psychological differences between early- and late-onset psoriasis: a study of personality traits, anxiety and depression in psoriasis. Br J Dermatol. 2013;169(2):344–350.

Source: PubMed

Sponsors et collaborateurs

Les conditions médicales

Interventions en matière de drogue

3
S'abonner